Fragmin (dalteparin sodium injection)

Published Online: Tuesday, November 1, 2005

Eisai Inc (Teaneck, NJ) recently announced an in-license agreement with Pfizer Inc for exclusive US rights to promote Fragmin. The company will also assume responsibility for postmarketing studies and product distribution, as well as book all US sales. Fragmin is a clot-preventing agent, for subcutaneous injection only, in a class of drugs known as low-molecular-weight heparins. In the United States, Fragmin is indicated for prevention of deep vein thrombosis, which may lead to pulmonary embolism, in patients undergoing hip replacement surgery, in at-risk patients undergoing abdominal surgery, or in at-risk acutely ill patients whose mobility is severely restricted. The product is also approved for prophylaxis of ischemic complications resulting from unstable angina and non-Q-wave myocardial infarction, when used with aspirin. For more information, visit www.fragmin.com.




Latest Articles
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.
Police and a CVS pharmacy are on the lookout for a man who stole several boxes of diabetic test strips.
The FDA has approved Merck’s supplemental new drug application for single-dose fosaprepitant dimeglumine for injection.
Latest Issues
$auto_registration$
VSEO N/A